| Literature DB >> 28219338 |
Raquel Bravo-Escobar1, Alicia González-Represas2, Adela María Gómez-González3, Angel Montiel-Trujillo3,4, Rafael Aguilar-Jimenez3, Rosa Carrasco-Ruíz3, Pablo Salinas-Sánchez5.
Abstract
BACKGROUND: Previous studies have documented the feasibility of home-based cardiac rehabilitation programmes in low-risk patients with ischemic heart disease, but a similar solution needs to be found for patients at moderate cardiovascular risk. The objective of this study was to analyse the effectiveness and safety of a home-based cardiac rehabilitation programme of mixed surveillance in patients with ischemic cardiopathology at moderate cardiovascular risk.Entities:
Keywords: Exercise therapy; Myocardial ischemia; Rehabilitation; Telemedicine
Mesh:
Year: 2017 PMID: 28219338 PMCID: PMC5319164 DOI: 10.1186/s12872-017-0499-0
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Classification criteria
| Risk | Clinical Variables | Complementary Tests | Physical Capacity |
|---|---|---|---|
| Low | Age <50 years | No signs of ischemia. | ≥7 METS |
| Moderate | Age >50 years | Effort angina or mild signs of ischemia. | >5 METS |
| High | Killip II or III | Severe ischemia. ST depression of >2 mm at a rate of less than 135 beats per minute. | <5 METS |
Fig. 1Flowchart of the study design
Baseline characteristics of the study population
| Hospital ( | Home ( |
| |
|---|---|---|---|
| Age (years) | 55.64 (11.35) | 56.50 (6.01) | ns |
| Sex Male n (%) | 14 (100) | 14 (100) | ns |
| Risk factors | |||
| Hypertension n (%) | 11 (78.57) | 9 (64.28) | ns |
| Hyperlipidaemia n (%) | 5 (35.71) | 7 (50) | ns |
| Diabetes n (%) | 1 (7.14) | 6 (42.85) | 0.029* |
| Overweight n (%) | 8 (57.14) | 5 (35.71) | ns |
| Obese n (%) | 6 (42.85) | 6 (42.85) | ns |
| BMI (kg/m2) | 29.29 (3.62) | 28.64 (3.65) | ns |
| Waist-hip ratio (cm) | 106.42 (8.84) | 104.14 (10.21) | ns |
| Current smokers n (%) | 2 (14.28) | 2 (14.28) | ns |
| Coronary artery disease | |||
| Monovessel n (%) | 3 (21.42) | 8 (57.14) | ns |
| Double vessel n (%) | 5 (35.71) | 4 (28.57) | ns |
| Triple vessel n (%) | 5 (35.71) | 1 (7.14) | ns |
| Revascularization technique | |||
| CABG n (%) | 2 (14.3) | 1 (7.1) | ns |
| PCI n (%) | 11 (78.6) | 11 (78.6) | ns |
| PCI & CABG n (%) | 1 (7.1) | 2 (14.3) | ns |
| Blood pressure | |||
| Systolic blood pressure (mmHg) | 115.35 (23.73) | 119.35 (24.05) | ns |
| Diastolic blood pressure (mmHg) | 69.28 (11.41) | 71.50 (9.48) | ns |
| Exercise stress test | |||
| Exercise time (min) | 5.47 (2.08) | 5.84 (2.66) | ns |
| METS | 7.10 (1.97) | 7.55 (2.77) | ns |
| Heart rate maximal (bpm) | 132.84 (16.11) | 106.21 (32.58) | 0.02* |
| % of predicted peak HR. | 79.86 (12.27) | 65.10 (20.09) | 0.02* |
| Hypertension response n (%) | 5 (41.7) | 4 (28.6) | ns |
| Clinical positive response n (%) | 1 (7.1) | 0 (0) | ns |
| Electrical positive response n (%) | 2 (14.3) | 0 (0) | ns |
| Ejection Fraction (EF) | 52.33 (3.51) | 51.00 (7.9) | ns |
| Laboratory values | |||
| Total cholesterol (mg/dL) | 130.50 (32.16) | 145.71 (29.35) | ns |
| HDL cholesterol (mg/dL) | 37.85 (8.07) | 39.84 (9.21) | ns |
| LDL cholesterol (mg/dL) | 67.17 (23.19) | 73.68 (25.62) | ns |
| Triglycerides (mg/dL) | 161.21 (72.31) | 148.35 (58.16) | ns |
| Glucose (mg/dL) | 94.92 (13.56) | 111.00 (28.03) | ns |
| HbA1c | 5.62 (1.05) | 5.72 (0.93) | ns |
| Health-related quality of life | |||
| SF-36 (score) | 53.33 (19.80) | 48.44 (20.89) | ns |
Values are presented as mean (SD) unless stated otherwise
* Significance level p < 0.05
Prescribed medication to patients
| Medication | Hospital ( | Home ( |
|---|---|---|
| Antiplatelet agents | - | - |
| Acetylsalicylic acid | 14 | 14 |
| Clopidrogrel | 3 | 5 |
| Tricagrelor | 8 | 5 |
| Rivaroxavan | - | - |
| Plasugrel | 2 | 4 |
| Stomach protectors | 14 | 14 |
| Antiarrhythmics | ||
| Bisoprolol | 13 | 13 |
| Carvedilol | 1 | - |
| Ranazolina | - | 1 |
| Antihypertensives | - | - |
| IECA | 10 | 9 |
| ARA-II | 3 | 4 |
| Diuretic | 4 | 4 |
| Amlodipino | 4 | 1 |
| Oral antidiabetic agents | 1 | 7 |
| Insulin | 1 | 3 |
| Anxiolytic | 8 | 7 |
| Statins | 14 | 14 |
| Hipnotic | 2 | 2 |
| Antidepressant | 1 | 2 |
| Epleronona | 1 | 1 |
Measures results obtained before and after the two different cardiac rehabilitation programs
| Hospital based cardiac rehabilitation program | Home based cardiac rehabilitation program |
|
| |||
|---|---|---|---|---|---|---|
| Before | After | Before | After | |||
| METS | 7.10 (1.97) | 8.45 (1.71) | 7.55 (2.77) | 8.28 (2.62) |
| 0.49 |
| Exercise time (min) | 5.47 (2.08) | 6.87 (1.67) | 5.84 (2.66) | 6.38 (1.80) |
| 0.32 |
| Heart rate maximal (bpm) | 132.84 (16.11) | 123.38 (17.38) | 107.23 (32.58) | 123.84 (22.61) |
|
|
| % of predicted peak HR. | 79.86 (12.27) | 75.16 (9.2) | 65.10 (20.09) | 75.81 (14.07) |
|
|
| Borg Scale | 12.57 (1.15) | 13.57 (1.22) | 13.07 (1.49) | 13.69 (1.18) |
| 0.54 |
| Recovery rate 1 min (bpm) | 13.85 (5.02) | 17.21 (6.29) | 11.63 (7.41) | 13.81 (4.46) |
| 0.54 |
| BMI (kg/m2) | 29.29 (3.62) | 29.08 (37.6) | 28.60 (3.80) | 29.08 (4.33) | 0.54 | 0.13 |
| Waist-hip ratio (cm) | 106.42 (8.84) | 105.35 (9.96) | 103.84 (10.56) | 103.69 (10.59) | 0.24 | 0.37 |
| Total cholesterol (mg/dL) | 130.50 (32.16) | 138.21 (25.41) | 142.66 (29.44) | 135.91 (23.43) | 0.91 | 0.10 |
| HDL cholesterol (mg/dL) | 37.85 (8.07) | 20.57 (8.75) | 39.45 (8.99) | 40.45 (7.01) | 0.24 | 0.58 |
| LDL cholesterol (mg/dL) | 62.17 (23.19) | 68.62 (16.63) | 70.30 (26.14) | 61.13 (15.50) | 0.74 | 0.06 |
| Triglycerides (mg/dL) | 161.21 (72.31) | 161.07 (102.20) | 149.83 (61.56) | 160.08 (84.71) | 0.77 | 0.76 |
| Glucose (mg/dL) | 94.92 (13.56) | 104.07 (27.73) | 109.83 (28.67) | 106.75 (14.61) | 0.57 | 0.26 |
| HbA1c | 5.62 (1.05) | 5.75 (1.30) | 6.05 (1.18) | 6.15 (1.36) | 0.35 | 0.90 |
| Systolic blood pressure (mm Hg) | 115.76 (24.65) | 119.23 (19.45) | 119.35 (24.05) | 120.35 (16.69) | 0.65 | 0.80 |
| Diastolic blood pressure (mm Hg) | 69.23 (11.87) | 72.30 (11.65) | 71.50 (9.48) | 72.14 (11.21) | 0.45 | 0.62 |
| SF-36 (score) | 53.33 (19.80) | 63.63 (21.00) | 47.93 (22.57) | 43.62 (24.20) |
|
|
Data are presented as mean values (SD)
aSignificance level for the hypothesis of no time effect
bSignificance level for the hypothesis of no time x group effect (difference in outcome improvement between the two programs)
*Significance level p < 0.05
**Significance level p < 0.01
Significant values are highlighted in bold